Annexin announces outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN, HONGKONG, SWITZERLAND, SINGAPORE, NEW ZEALAND, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFULAnnexin Pharmaceuticals AB (publ) (“Annexin” or “the Company”) announces today that the rights issue of shares and warrants of series TO3 (“Units”) (the “Rights Issue”) has been completed. 42,011,156 Units, approximately 71.4 per cent of the Rights Issue, were subscribed for by the exercise of unit rights